<a href="https://laohu8.com/S/BBIO">BridgeBio Pharma</a> Announces New Equity Compensation Plan for Employees with Inducement Grants
BridgeBio Pharma Inc., a biopharmaceutical company focused on genetic diseases, has announced the approval of new equity compensation grants for its employees. The company's board of directors' compensation committee has approved restricted stock units (RSUs) for new employees as part of its Amended and Restated 2019 Inducement Equity Plan. The recent approvals include RSU grants covering a total of 33,684 shares for 13 employees on September 5, 2025, 32,145 shares for 16 employees on August 4, 2025, and 73,991 shares for 20 employees on July 14, 2025. Additionally, on June 6, 2025, RSU grants covering 98,348 shares were approved for 25 employees. The vesting schedule for these RSUs begins with one-fourth of the shares vesting in mid-2026, and the remainder vesting in equal quarterly installments over three years.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9526068-en) on September 10, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.